OncoDxRx

OncoDxRx's Spectacular PGA Technology Besides providing dazzling gene-to-drug technology—the latest liquid biopsy craze—is digging into rich cell-free mRNA data sets and uncovering meaningful results Gene-to-drug is poised to become the “next big thing” in precision medicine. On the strength of new PGA technologies, it promises to elevate an ambitious concept—the matching and prediction of the best drug(s) at the patient’s and molecular levels. Although the concept has been around for decades, transformational technologies are taking it to new heights. Indeed, PGA technology promises to usher gene-to-drug into a bright new era. We use lots of fancy terms, but gene-to-drug still means predicting drug response from gene patterns or signatures. Why is PGA so powerful? According to OncoDxRx, it provides the ability to understand the relationship between gene signature and mechanism of action of drug. PGA is expected to be especially valuable as a means of broadening the coverage of tailored personalized diagnostics and therapeutics for those cancer patients currently excluded from precision medicine, i.e., no actionable mutation detected following current NCCN testing workup. A tumor is not a tumor is not a tumor. Each tumor has a profile that depends on the tumor’s location and what the tumor microenvironment is. The PGA technology enabled an analysis of the gene expression fingerprints that predict to be responsive to certain drug(s). More specifically, the technology allowed hundreds of existing anticancer drugs to be examined in a single analysis. OncoDxRx’s team was able to take patient’s blood, profile gene expression, and report out a list of most effective, effective and less effective drugs within 5 days. Moreover, the team can deconvolute which class of drugs were most likely to have an effect. PGA is impressive not just for the depth of its analyses, but for the breadth of its applications. We welcome investment, licensing and partnership! #technology #medicine #data #testing #cancer #oncology #liquidbiopsy #team #precisiononcology

Ensure favorable outcomes and QOL of our patients with OncoMRD Our high-performance solutions offer sensitive, specific detection of residual tumor activity. This exclusive and transformative OncoMRD test safeguard patients from survived tumor cells that could compromise efficacy, increase recurrence risk, and jeopardize patient outcomes. #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx #genomics #NGS #CRISPR #gene #geneexpression #artificialintelligence #machinelearning #sequencing #NGS #cancerresearch #personalizedmedicine #targetedtherapy #PrecisionOncology #Therapy #earlydetection #MRD 

Never compromise accuracy for speed With OncoDxRx, you get both. Information is power Our tests give you the power to make informed health decisions for you, loved ones, or your patients. #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx #genomics #NGS #CRISPR #gene #geneexpression #artificialintelligence #machinelearning #sequencing #NGS #cancerresearch #personalizedmedicine #targetedtherapy #PrecisionOncology #Therapy #earlydetection #MRD 

All-In drug response prediction makes PGA a must for cancer treatment selection PGA’s main strength is to optimize the gene-drug mapping process by assigning a patient’s gene signature to the best performing drugs on the market, including approved, clinical trial and investigational candidates. What is decisive with PGA is the “all-in” capability to screen, map, identify and rank drug efficacy/response from a library of 700+ cancer drugs to accelerate the tempo of clinical treatment decision-making. The PGA technology is considerably more powerful than the current biomarker testing (or companion diagnostics) that it will complement. “The standard-of-care biomarker testing is optimized for genetic mutation detection and its patient eligibility rate is so low that it can only qualify 20-30 percent of cancer patients for precision medicine as responders.” “The new PGA will predict the most effective drugs for the 70-80 percent non-responders with a high level of accuracy, therefore completing the puzzle.” The real-time and real-life capability is another advantage of PGA. “It helps us to significantly increase the prediction power of drug response and so it contributes to overall test accuracy. Critical data, such as the ranking of drug efficacies, can also be called,” said OncoDxRx. #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx #genomics #NGS #CRISPR #gene #geneexpression #artificialintelligence #machinelearning #sequencing #NGS #cancerresearch #personalizedmedicine #targetedtherapy #PrecisionOncology #Therapy #earlydetection #MRD

A responsibility to cancer patients: close the biomarker testing gap in precision oncology In response to the growing cancer threats, OncoDxRx is ramping up its drug response prediction (DRP) capabilities. OncoDxRx has launched PGA (Patient-derived Gene expression-informed Anticancer drug efficacy) test, and plans are underway to increase its adoption significantly. The strategic focus is on expanding PGA market and integrating into current precision oncology testing workup, reinforcing the lessons learned from personalized and precision medicine. The war against cancer has underscored the importance of DRP capability in contemporary targeted therapy. The industry has deployed a wide range of biomarker testing (or companion diagnostics) for treatment decision-making, transforming clinical doctrines. Unfortunately, NGS biomarker testing only qualify 20-30% of cancer patients, if taking into account of response rate, only about 10-20% patients actually benefit from precision medicine. OncoDxRx’s PGA provides unprecedented real-time real-life drug-mapping capability, enabling faster decision-making and more precise drug efficacy prediction. For clinical labs like those using NGS comprehensive genomic profiling, PGA gap-fills the unmet need for patient “NON-RESPONDERS”, complements biomarker testing, while completing test menu and benefiting many more cancer patients. OncoDxRx’s focus on PGA-powered DRP tactics marks a significant shift in treatment selection strategy for those patients unresponsive to precision medicine. By leveraging the experience of PGA development and continuously improving its technological capabilities, OncoDxRx is positioning itself at the forefront of modern theranostics. #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx #genomics #NGS #CRISPR #gene #geneexpression #artificialintelligence #machinelearning #sequencing #NGS #cancerresearch #personalizedmedicine #targetedtherapy #PrecisionOncology #Therapy #earlydetection #MRD 

In response to the growing cancer threats, OncoDxRx is ramping up its drug response prediction (DRP) capabilities. OncoDxRx has launched PGA (Patient-derived Gene expression-informed Anticancer drug efficacy) test, and plans are underway to increase its adoption significantly. The strategic focus is on expanding PGA market and integrating into current precision oncology testing workup, reinforcing the lessons learned from personalized and precision medicine. The war against cancer has underscored the importance of DRP capability in contemporary targeted therapy. The industry has deployed a wide range of biomarker testing (or companion diagnostics) for treatment decision-making, transforming clinical doctrines. OncoDxRx’s PGA provides unprecedented real-time real-life drug-mapping capability, enabling faster decision-making and more precise drug efficacy prediction. For clinical labs like those using NGS comprehensive genomic profiling, PGA gap-fills the unmet need for patient "non-responders", complement biomarker testing, while completing test menu and benefiting many more cancer patients. #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx #genomics #NGS #CRISPR #gene #geneexpression #artificialintelligence #machinelearning #sequencing #NGS #cancerresearch #personalizedmedicine #targetedtherapy #PrecisionOncology #Therapy #earlydetection #MRD 

Outsmarting Cancer Threats In the digital age, precision oncology faces challenges posed by rapidly advancing tumor evolution. Low patient response rate, therapeutic resistance, and disease relapse require continuous adaptation to stay ahead of the game and effectively gather complete intelligence " beyond tumor itself ". Healthcare must strike a delicate balance between financial burden and safeguarding patient outcome. Striking this balance is an ongoing challenge. OncoDxRx’s exclusive technology pipelines, comprised of PGA, OncoMRD and OncoMCED, are vital components of the company’s precision diagnostics apparatus. Their multifaceted biomarker panels, patient's own gene expression signatures, and in silico data analytics capabilities enable these assays to effectively address early detection, treatment selection, and therapeutic response monitoring challenges. By overcoming these challenges and leveraging technical expertise and knowhow, OncoDxRx is always one step ahead in the fight against cancer. #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx #genomics #NGS #CRISPR #gene #geneexpression #artificialintelligence #machinelearning #sequencing #NGS #cancerresearch #personalizedmedicine #targetedtherapy #PrecisionOncology #Therapy #earlydetection #MRD 

OncoDxRx is a next-gen technology leader in liquid biopsy-driven, trusted and sustainable precision oncology transformation with a strong portfolio of exclusive technologies. No company did more to engage with patient non-responders than OncoDxRx. There has been a renaissance of sorts for drug response prediction technologies in recent years in particular. Any of those alternative treatment options provided by PGA could offer cancer patients much more flexibility to respond to other drugs than targeted therapy, especially for non-responders. They would almost certainly offer greater benefit, speed, and accuracy compared to trial-and-error or educated guess work. As such, PGA-identified anticancer drugs would be able to strengthen therapeutic tools in clinicians’ possession. Coupled with fast turnaround and low-cost OncoDxRx plans for its exclusive diagnostics pipelines, PGA could be even more formidable weapons against cancer. PGA would also reduce the need to rely on the much more labor-intensive, time-consuming and expensive to operate NGS for the response prediction of targeted therapy, and to provide rapid support in the event of a refractory, metastatic or relapsed disease. PGA would just be better suited to providing treatment decision support in certain circumstances, too. If PGA is as vocal behind the scenes as the biomarker testing was in precision medicine, the precision oncology would end up looking very different over the next five years. #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx #genomics #NGS #CRISPR #gene #geneexpression #artificialintelligence #machinelearning #sequencing #NGS #cancerresearch #personalizedmedicine #targetedtherapy #PrecisionOncology #Therapy #earlydetection #MRD 

Personalized medicine, which tailors treatments to patients based on genetic and molecular profiles, offers a path toward more effective therapies and better patient outcomes. This field has been hindered by limited accessibility, low response rate and drug resistance. OncoDxRx’s mission is to address these challenges by providing expertise and knowhow to invent novel technologies such as PGA and OncoMRD. OncoDxRx’s initiative is designed to improve healthcare outcomes for patients worldwide by advancing patient-tailored therapies and making innovative treatments more accessible, especially for those patients "unresponsive to precision therapy". #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx #genomics #NGS #CRISPR #gene #geneexpression #artificialintelligence #machinelearning #sequencing #NGS #cancerresearch #personalizedmedicine #targetedtherapy #PrecisionOncology #Therapy #earlydetection #MRD 

At OncoDxRx, we are dedicated to empowering precision medicine with cutting-edge solutions and outstanding performance. The newly released PGA technology seamlessly combines best-in-class in vitro transcriptomic profiling and in silico drug-mapping analytics in one integrated testing platform. PGA unlocks simultaneous measurement of a panel of circulating cell-free mRNA (cfmRNA) biomarkers at subcellular functional resolution from a single patient sample. “This revolutionary technique tells us how active a tumor is and could allow doctors to assess ALL existing cancer drugs in a patient to give a more holistic assessment of disease so the most appropriate treatment can be selected,” OncoDxRx said. #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx #genomics #NGS #CRISPR #gene #geneexpression #artificialintelligence #machinelearning #sequencing #NGS #cancerresearch #personalizedmedicine #targetedtherapy #PrecisionOncology #Therapy #earlydetection #MRD